[New anticancer drugs: much ado about nothing?]
Abstract:
Multiple new cancer drugs have been marketed during the last decade, and among those many molecularly targeted agents. Their impact on clinical outcomes population-wide remains hard to measure. Are we merely seeing the development of expensive and toxic drugs that benefit a minority of patients, or are battles actually won in the war on cancer? Both epidemiologic trends and clinical trial data show that a patient's outcome today is significantly better than 10 or 20 years ago, in terms of cure rates and survival time for advanced disease.
Insights
New cancer drugs, particularly molecularly targeted agents, have improved patient outcomes. Epidemiologic and clinical data show better cure rates and survival times for advanced diseases compared to previous decades.
Area of Science:
- Oncology
- Pharmacology
- Epidemiology
Context:
- The last decade has seen the marketing of numerous novel cancer therapeutics, including many molecularly targeted agents.
- Assessing the population-wide impact of these new cancer drugs on clinical outcomes presents a significant challenge.
- Questions arise regarding the true benefit of these often expensive and toxic agents versus their impact on a minority of patients.
Purpose:
- To evaluate the overall impact of new cancer drugs, especially molecularly targeted therapies, on patient outcomes.
- To determine if recent advancements in cancer treatment have led to measurable improvements in cure rates and survival.
Summary:
- Analysis of epidemiologic trends and clinical trial data indicates a substantial improvement in patient outcomes over the past 10-20 years.
- These improvements are evident in increased cure rates and prolonged survival times for patients with advanced-stage cancer.
- The data suggests that recent therapeutic developments have contributed positively to the fight against cancer.
Impact:
- Patient outcomes in cancer treatment have significantly improved compared to previous decades.
- Enhanced cure rates and extended survival times for advanced disease demonstrate progress in oncology.
- The development and application of new cancer drugs appear to be contributing to a "war on cancer" victory.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes